Is an intravenous iron infusion indicated for a ferritin level of 29.8 ng/mL?

Iron Infusion for Ferritin of 29.8 ng/mL

Yes, intravenous iron infusion is indicated for a ferritin level of 29.8 ng/mL, as this value falls well below the target ferritin goal of 50 ng/mL in the absence of inflammation 1.

Diagnostic Threshold and Treatment Indication

A ferritin of 29.8 ng/mL definitively indicates iron deficiency. According to the most recent expert consensus guidelines, the goal ferritin is 50 ng/mL regardless of sex 1. Your patient's level is approximately 40% below this target, confirming absolute iron deficiency that warrants treatment.

When to Choose IV Over Oral Iron

The decision between oral and IV iron depends on specific clinical factors 2:

IV iron should be used if:

• The patient does not tolerate oral iron
• Ferritin levels do not improve with a trial of oral iron
• The patient has a condition where oral iron is unlikely to be absorbed (inflammatory bowel disease with active inflammation, post-bariatric surgery, celiac disease, autoimmune gastritis) 2

If none of these conditions apply, start with oral iron (ferrous sulfate once daily or every other day with vitamin C) 2. However, if any of these factors are present, proceed directly to IV iron.

Confirming Iron Deficiency

Before administering IV iron, verify the diagnosis by checking:

• Transferrin saturation (TSAT): A TSAT <20% has high sensitivity for diagnosing absolute or functional iron deficiency 1
• Complete blood count: To assess for anemia and mean corpuscular volume
• Consider the clinical context for inflammation, as ferritin can be falsely elevated as an acute phase reactant 1

With a ferritin of 29.8 ng/mL and no inflammation, iron deficiency is essentially certain.

IV Iron Formulation Selection

Choose formulations that replace iron deficits with 1-2 infusions 2. The preferred options include:

• Ferric derisomaltose (FDI): 1000 mg infusion or up to 20 mg/kg (max 1500 mg), diluted in 100 mL normal saline over 20-30 minutes 1
• Ferric carboxymaltose (FCM): Similar dosing convenience 1
• Iron sucrose: Requires multiple infusions, less preferred 2

Important Safety Considerations

All IV iron formulations have similar safety profiles 2:

• True anaphylaxis is very rare (<1% of patients experience moderate to severe reactions) 3
• Most reactions are complement activation-related pseudo-allergy (infusion reactions), not true anaphylaxis 2
• Ferric carboxymaltose carries a specific risk: 50-74% of patients develop hypophosphatemia (the 6H syndrome: hyperphosphaturic hypophosphatemia with elevated FGF23, hypovitaminosis D, hypocalcemia, secondary hyperparathyroidism) that can cause bone pain, osteomalacia, and fractures 3

Monitoring After Treatment

Do not check iron parameters within 4 weeks of IV iron infusion, as circulating iron interferes with assays and produces spurious results 1.

At 4-8 weeks post-infusion, check:

• CBC (hemoglobin should increase 1-2 g/dL within 4-8 weeks)
• Ferritin (target ≥50 ng/mL)
• TSAT (target ≥20%)

Expected Outcomes

Hemoglobin concentrations should increase within 1-2 weeks of treatment 1. Even in non-anemic patients with iron deficiency, IV iron significantly improves fatigue and quality of life, reflecting the non-hematological functions of iron 4, 5.

Frequency of Re-treatment

If the underlying cause of iron deficiency has been eliminated, a single total dose infusion should suffice 1. However, if ongoing losses exist (heavy menstrual bleeding, gastrointestinal bleeding, malabsorption), multiple administrations will be necessary with frequency dependent on the degree of blood loss or malabsorption 1.